New hope for tough lymphomas? study tests SAR444245 combo – but ends early
NCT ID NCT05179603
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times
Summary
This study tested an experimental drug called SAR444245, alone or with pembrolizumab, in 14 people aged 12 and older with B cell lymphoma that returned or didn't respond to prior treatments. The goal was to see if the drug could shrink tumors. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number : 0320005
CABA, Buenos Aires, 1430, Argentina
-
Investigational Site Number : 1520001
Temuco, 4800827, Chile
-
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, 7500921, Chile
-
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, 7500653, Chile
-
Investigational Site Number : 1520004
Viña del Mar, Valparaiso, 2540488, Chile
-
Investigational Site Number : 7240001
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
-
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], 08036, Spain
-
Investigational Site Number : 7240004
Madrid / Madrid, Madrid, Comunidad de, 28040, Spain
Conditions
Explore the condition pages connected to this study.